Peter Lichtlen founded Numab Therapeutics AG.

He is Director & Chief Medical Officer at this company. Dr. Lichtlen is also on the board of Lysogene SA and Numab Innovation AG and Member of FMH Swiss Medical Association and Member of Swiss Association of Pharmaceutical Professionals, Inc.

In his past career he occupied the position of Chief Medical Officer at Sucampo Pharmaceuticals, Inc., Head-Clinical Research & Development at ESBATech AG and Senior Medical Officer & VP-European Operations at Sucampo GmbH.

He received a doctorate from the University of Zurich.